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Olfactory dysfunction is a frequent nonmotor symptom in idiopathic Parkinson’s disease (PD) andmay be considered as an early clinical
feature of the disease preceding motor symptoms by years. According to recent neuropathological staging concepts, impaired olfaction
is assumed to indicate an early pathological process and might be associated with structural changes in the brain. A morphometric
analysis of magnetic resonance images [voxel-based morphometry (VBM)] was used to investigate gray matter atrophy related to
psychophysically measured scores of olfactory function in early PD patients (n 15, median Hoehn and Yahr stage 1.5), moderately
advanced PD patients (n 12,medianHoehn and Yahr stage 2.5), and age-matched healthy controls (n 17). In PD patients, but not in
controls, cortical atrophy in olfactory-related brain regions correlated specifically with olfactory dysfunction. Positive correlations
between olfactory performance and gray matter volume were observed in the right piriform cortex in early PD patients and in the right
amygdala in moderately advanced patients. The results provided first evidence that olfactory dysfunction in PD is related to atrophy in
olfactory-eloquent regions of the limbic and paralimbic cortex. In addition, olfactory-correlated atrophy in these brain regions is con-
sistent with the assumption that olfactory impairment as an early symptom of PD is likely to be associated with extranigral pathology.
Introduction
It is now widely accepted that early nonmotor signs indicate
preclinical stages of Parkinson’s disease (PD) before the onset of
motor symptoms. Consistent with this clinical observation, Braak’s
neuropathological staging concept (Braak et al., 2003) proposes
that important pathological processes during the presymptom-
atic phase may occur already in other, primarily non-motor-
related brain regions. While cardinal motor symptoms in PD are
closely related to a severe loss of dopaminergic cells in the nigro-
striatal pathway, early clinical features are more likely to be asso-
ciated with extranigral pathology. A prevalent symptom at early
stages of PD is olfactory impairment (Ansari and Johnson, 1975).
Results from postmortem studies revealed pathological changes
(Lewy body formation) in the olfactory bulb (Huisman et al.,
2008) but also in other brain regions related to olfaction, such as
the anterior olfactory nucleus (Pearce et al., 1995), the piriform
cortex (Braak et al., 2003; Silveira-Moriyama et al., 2009), the
amygdaloid complex (Harding et al., 2002; Braak et al., 2003), the
entorhinal cortex, and the hippocampal formation (Braak et al.,
2003). Using functional magnetic resonance imaging in PD pa-
tients, our previous findings indicated altered neuronal activity in
the amygdaloid complex and hippocampal formation during ol-
factory stimulation (Westermann et al., 2008; Welge-Lu¨ssen et
al., 2009). On this basis, we hypothesized that pathophysiology of
olfaction in PD is associated with structural abnormalities, for
instance with regional atrophy in brain regions involved in olfac-
tion. For in vivo studying of structural brain anatomy, voxel-
basedmorphometry (VBM) has been proven to correlate clinical
features with gray matter changes in PD, such as executive and
visuospatial impairment (Nagano-Saito et al., 2005) and depres-
sion (Feldmann et al., 2008). However, olfactory dysfunction as
an early symptom of PD has not yet been investigated with re-
spect to structural changes in the brain. Aiming at this question,
we performed a morphometric analysis of magnetic resonance
images (VBM) to identify graymatter atrophy related to olfactory
dysfunction in three study groups: early PD patients, moderately
advanced PD patients, and healthy controls.
Materials andMethods
Subjects.We investigated 27 patients with PD diagnosed according to the
UK PD Society Brain Bank diagnostic criteria (Gibb and Lees, 1988) and
17 age-matched healthy controls (9 men, mean age: 63.1 years, range:
52–72 years). None of the control subjects had a history or signs of major
neurological disorders. Written informed consent was obtained from all
participants. The study was approved by the Ethics Committee of the
University Hospital of Basel, Switzerland. According to the Hoehn and
Yahr scale (H&Y), early PD patients (n  15, 11 men, mean age: 60.3
years, range: 44–71 years) had a median score of 1.5, while moderately
advanced PDpatients (n 12, 6men,mean age: 61.7 years, range: 46–69
years) had a median score of 2.5 (Hoehn and Yahr, 1967). The median
Unified Parkinson’s Disease Rating Scale score was 26 (range: 4–41) in
early patients and 30 (range: 18–60) in moderately advanced patients
(Fahn and Elton, 1987). The median duration of disease was 3.2 and 8.8
years, respectively. All subjects were nondemented [Mini-Mental State
Examination (MMSE) (Folstein et al., 1975), MMSE score28] and did
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not exhibit significant signs of depression [Beck Depression Inventory
(BDI) (Beck et al., 1961), BDI score15].
Olfactory testing. Olfactory function was assessed birhinally using the
standardized “Sniffin’ Sticks” test battery (Burghart) that included non-
verbal odor threshold (T), nonverbal discrimination (D), and verbal
identification (I) tests (Hummel et al., 1997; Kobal et al., 2000).
The sumof scores obtained from the three subtests threshold, discrim-
ination, and identification gives a composite measure of olfactory func-
tion, i.e., the TDI-score (see supplemental text 1, available at www.
jneurosci.org as supplemental material). Based on the TDI score,
olfactory function is classified as normosmic (TDI30), hyposmic (TDI
16–30), and functionally anosmic (TDI 15). On average, early and
moderately advanced PD patients were hyposmic as indicated by mean
scores of 21.8 (range: 12.3–30.3) and 21.3 (range: 15.0–32.5), respec-
tively. The mean olfactory scores did not differ between both PD groups
[p  0.85, not significant (n.s.)]. Healthy controls were, on average,
normosmic (mean score: 33.9, range: 27.0–43.0) and had a better olfac-
tory performance than early and advanced PD patients (for both p 
0.00001).
Data acquisition and analysis. Images were acquired on a 1.5 T Siemens
Sonata MR scanner (Siemens) using a T1-weighted 3D magnetization
prepared gradient rapid acquisition gradient echo (MPRAGE) sequence
(echo time: 3.68 ms, repetition time: 1900 ms, flip angle: 10°, voxel size:
1  1  1 mm). VBM has been applied to
detect alterations in gray matter volume that
are associated with olfactory performance in
olfactory-related regions of the limbic and
paralimbic cortex in PD patients and normal
healthy controls. Data analysis was performed
using VBM5 toolbox (http://dbm.neuro.
uni-jena.de/vbm/, version 1.18) for Statistical
Parametric Mapping (Friston et al., 1995)
(SPM5). The unified segmentation approach
uses prior tissuemaps to estimate the probabil-
ity of each voxel belonging to the respective
tissue class, i.e., gray and white matter (Ash-
burner and Friston, 2005).However, tissue pri-
ors derived from young, healthy subjects could
introduce a segmentation bias in our specific
study groups. To avoid such bias, segmenta-
tion based on voxel intensity alone has been
applied (Gaser et al., 2007). The resulting tissue
maps were modulated with the Jacobian deter-
minants of the deformation parameters ob-
tained by normalization to theMNI (Montreal
Neurological Institute) standard space. A cus-
tomized template consisting of all subjects in
our study was created to improve the quality of
normalization (Wilke et al., 2008). Finally, im-
ages were smoothedwith an isotropicGaussian
kernel of 8 mm.
The present analysis was designed to assess
cortical atrophy that correlated with olfactory
performance (TDI score). Changes of gray
matter volume dependent on TDI scores were
assessed in a multiple regression analysis in-
cluding total gray matter volume as nuisance
covariate. In PD patients, this analysis was ad-
ditionally corrected for the H&Y score and
disease duration. Based on our a priori hypoth-
esis, a statistical threshold of p 0.005 (uncor-
rected) with a cluster extent of 800 voxel was
used. The cluster extent threshold has been
corrected for anisotropy of smoothness (Ha-
yasaka et al., 2004). The correlation coefficients
were computed as average across all voxels of
each cluster in the respective regions. Group
comparisons in correlations were considered
significant at p  0.005 (uncorrected). Corre-
lation maxima were reported as Z-scores and
coordinates in the MNI space. The investigator was blinded with regard
to group assignment and scores from clinical examination including
motor and olfactory scores.
Results
In PDpatients, but not in controls, graymatter volume correlated
positively with increasing scores of olfactory function as obtained
by psychophysical measurements. The early PD group showed a
significant correlation of gray matter volume and olfactory per-
formance in a primary olfactory region, namely the right piri-
form cortex (Fig. 1a). Moderately advanced patients exhibited a
correlative effect in the right amygdaloid complex (Fig. 1b), a
region corresponding to secondary olfactory projection zones. It
has to be noted that the linear increase of graymatter volumewith
better olfactory functionwasmost significant in olfactory-related
brain regions in both PD groups. The cluster-level inference in-
dicated that the clusters in the piriform cortex and amygdalawere
significant at p 0.007 and p 0.003, respectively (Fig. 1c,d). In
contrast, controls showed no significant correlation in these
brain regions (Fig. 1c,d). Effects of olfactory-correlated atrophy
Figure 1. Olfactory-associated cortical atrophy in PD patients. a, b, Gray matter volume correlated significantly with scores of
olfactory function: right piriform cortex (29, 7,20; Z-score 4.0) in early PD patients (a) and right amygdala (24, 0,27;
Z-score3.7) inmoderately advancedPDpatients (b). R, Patient’s right side. c,d, The correlationplots show that the relative gray
matter volumedecreaseswith lower scores of olfactory function (mean-centered smell test score) in the piriform cortex (c) and the
amygdala (d). Additional plots illustrate the correlation in both brain regions for controls. The correlation coefficients (r) were
computed as average across all voxels of each cluster in the respective regions after correcting the cluster extent for anisotropy of
smoothness. The statistical significancep relates to this cluster-level correction (seeMaterials andMethods). Negative values of the
smell test indicate poor olfactory function, and positive values indicate a better olfactory function.
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in each of the PD groups were confirmed by group comparisons.
When compared to controls, early PD patients showed a stronger
correlative effect in the right piriform cortex (28, 6, 19; p 
0.002, z 2.96) and advanced patients in the right amygdala (23,
1,23; p 0.005, z 2.76). These effects were also specific for
each of the PD groups. In early PD patients, correlation was sig-
nificantly higher in the right piriform cortex than in advanced
patients (28, 7,20; p 0.004; z 2.65). Vice versa, in advanced
patients, a trend for higher correlation was observed in the right
amygdala (19, 0,23, p 0.02, z 2.0).
The comparison on total intracranial volume (TIV) and gray
matter volume (GMV) did not show any difference between all
groups studied (supplemental Fig. 1, available at www.jneurosci.
org as supplemental material).
Discussion
In this study, VBMwas applied to detect graymatter atrophy that
correlated with scores of olfactory function in PD patients and
controls. Our results suggest that olfactory dysfunction in PD is
associated with atrophy in olfactory-eloquent regions of the lim-
bic and paralimbic cortex andmight therefore not be restricted to
deficient sensory transmission in the olfactory bulb (Huisman et
al., 2008). Further analysis showed that olfactory-related atrophy
is not a consequence of generalized brain atrophy but seems to be
rather a regional effect; total intracranial and gray matter vol-
umes did not differ between all groups. Moreover, these local
correlative effects were confirmed as specific features of PD by
group comparisons indicating that the correlation between olfac-
tory scores and graymatter atrophy is significantly higher in each
of the PD groups than in normal controls.
The positive correlation of better olfactory performance with
increasing gray matter volume in early PD patients implies that
the piriform cortex contributes critically to normal olfactory
function. However, it is noteworthy that the function of the piri-
form cortex extends beyond merely unimodal sensory process-
ing. Its involvement in complex aspects of odor information
processing, such as olfactory associative learning, indicates that
this region also plays a role in establishing cross-modal associa-
tions (Gottfried et al., 2002, 2004; Boyle et al., 2007; Hummel et
al., 2009). Access to cross-modal associations is also necessary for
successful retrieval of chemosensory information when odors are
identified with the help of verbal descriptors. Verbal odor iden-
tification was part of the olfactory assessment in the present
study. Our finding of an olfactory-correlated atrophy in the piri-
form cortex partly provides an explanation for deficits of PD
patients on this task (Doty et al., 1988, 1992).
In moderately advanced PD patients, olfactory performance
correlated positively with gray matter volume in the amygdala.
This finding is consistent with postmortem studies suggesting
that substantial cell loss accompanied by high densities of Lewy
bodies in this brain region contributes to impaired olfaction
(Harding et al., 2002). However, our results imply that olfactory
dysfunction is associated with degenerative changes of the amyg-
dala at earlier stages of PD andnot only at final stages inwhich the
disease has reached its fully clinical extent. Olfactory perception
involves processes in the amygdala to evaluate the affective value
of stimuli (Zald and Pardo, 1997; Winston et al., 2005). Thus,
olfactory-correlated atrophy in this brain region could indicate
that PD patients have difficulties to assess the emotional valence
of olfactory stimuli. Indirect support for this interpretation
comes from our previous fMRI study that showed reduced activ-
ity in the amygdala in PD patients during olfactory stimulation
(Westermann et al., 2008).
The reason for this group-specific atrophy related to olfaction
in both PD groups remains speculative. The comparison of
olfactory-correlated atrophy between the PD groups showed a
significantly higher correlation in the piriform cortex in early PD
patients than in advanced patients. In advanced patients, a trend
for higher correlation could be demonstrated in the amygdala.
The observed correlative effects are independent from disease
severity (H&Y score) and disease duration as both variables were
included as covariates in the regression analysis. However, it has
to be considered that both parameters are related to the symp-
tomatic phase of PD, i.e., after onset of cardinalmotor symptoms.
In contrast, olfactory impairment as an early symptom indicates
the presymptomatic (nonmotor) phase of the disease. Possibly,
our finding of a group-specific correlation between cortical atro-
phy andolfactory impairment suggests that extranigral pathology
has progressed in regions of the olfactory cortex. This interpreta-
tion is consistent with the previously mentioned spreading of
PD-related brain lesions from the anterior olfactory nucleus
(stage 1) to the piriform cortex and different subnuclei of the
amygdala (stage 3/4) (Braak et al., 2003). In earlier affected brain
areas, it might therefore no longer be possible to show a correla-
tion at later stages of the disease. Thus, a stronger atrophy of the
piriform cortex could explain themissing correlative effect in the
moderately advanced PD group.
In addition, a correlation of olfactory ability with atrophy in
regions of the nigrostriatal system in either patient group was
absent emphasizing the role of extranigral pathology on impaired
olfaction in PD.
Summarizing, the results provide first evidence that olfactory
impairment is a valuable biomarker to reveal progressive cortical
atrophy during early and moderately advanced stages of PD.
Concerning disease progression, olfactory symptoms in PD indi-
cate a pathological process that seems to be present in parallel to
the depletion of the nigrostriatal dopaminergic pathway. In view
of an early, extranigral pathology, morphometric data together
with the assessment of olfactory function could be relevant to
identify patients in presymptomatic stages of PD.
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